

Supplemental Table 2. Antibiotic non-susceptibility in Gram-negative organisms isolated from corneal ulcers at Aravind Eye Hospital, Madurai, India, from 2002 to 2013. Values indicate the number of resistant isolates over the total number of isolates tested. Susceptibility breakpoints were adopted from the Clinical and Laboratory Standards Institute (CLSI) unless otherwise stated.

	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
P. aeruginosa												
Ofloxacin	12/52	19/47	14/58	10/74	4/82	13/84	9/105	8/65	6/97	12/79	8/73	1/71
Ciprofloxacin	7/31	7/49	9/58	10/74	4/82	12/84	9/107	8/66	8/97	12/80	7/73	2/69
Gatifloxacin ^a					4/82	13/84	8/107	6/66	6/97	9/80	6/73	1/71
Levofloxacin							9/106	7/66	7/97	9/80	7/73	1/70
Gentamicin	9/52	9/50	9/58	13/74	14/82	15/84	19/107	6/66	5/97	11/80	7/73	4/71
Tobramycin	14/52	6/49	9/58	7/74	5/82	13/84	10/107	6/66	3/97	9/80	7/73	2/70
Amikacin	6/52	7/50	9/58	13/72	4/82	10/84	21/106	10/65	8/97	8/79	6/69	1/70
Ceftazidime					4/82	3/84	9/103	1/65	1/97	11/80	5/71	2/69
Enterobacteriaceae												
Ofloxacin	1/10	0/7	1/9	0/3	1/9	0/6	0/6	3/12	5/13	3/12	0/13	2/10
Ciprofloxacin	0/10	1/7	0/9	0/3	1/9	1/6	1/6	3/12	5/13	4/12	1/13	2/10
Gatifloxacin					1/9	0/6	0/6	3/12	5/13	2/12	0/13	2/10
Levofloxacin							0/6	3/12	5/13	3/12	1/13	2/10
Chloramphenicol	4/10	1/7	2/9	0/3	2/9	1/6	0/6	1/12	5/13	4/12	1/13	3/10
Gentamicin	4/10	1/7	1/9	1/3	1/9	2/6	0/6	2/12	5/13	2/12	1/13	1/10
Tobramycin	3/10	2/7	0/9	1/3	1/9	2/6	0/6	2/12	6/13	2/12	1/13	2/10
Amikacin	2/10	2/7	0/9	0/3	0/9	1/6	0/6	2/12	2/13	2/12	1/13	0/10
Ceftazidime					0/9	2/6	0/6	2/12	7/13	3/12	1/13	2/10

^a Non-susceptibility defined using gatifloxacin breakpoints for *Enterobacteriaceae* from the CLSI